The SATB2 immunohistochemical marker has been shown to help distinguish osteosarcomas of long bones, including the small-cell variant, from their malignant bone tumor mimickers, such as Ewing sarcomas [20]. This evidence concerns the gene SATB2 and osteosarcoma.